close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Annovis Bio Inc.

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS TRAW
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Completes Full Patent Transfer to Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis to Attend the AAIC 2025 with Four Poster Presentations
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis to Host Webinar and Live Q&A on June 24, 2025
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio Appoints Hui Liu as Director of Biostatistics
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces New Publication in a Peer-Reviewed Journal
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
From Annovis Bio Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today